Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.38 |
| ▸ | PPARD | Q03181 | 6/20 | 0.38 |
| ▸ | PPARA | Q07869 | 6/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147859 | 1.00 | CES2 (0.39) | CES2CES1TSHRALDH1A1LMNA | |
| SCHEMBL1012970 | 0.91 | TERT (0.50) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL845976 | 0.84 | CES2 (0.41) | CES2CES1TSHRALDH1A1HSD17B10 | |
| SCHEMBL4947180 | 0.84 | CES2 (0.41) | CES2CES1TSHRALDH1A1HSD17B10 | |
| SCHEMBL845975 | 0.84 | CES2 (0.41) | CES2CES1TSHRALDH1A1HSD17B10 | |
| SCHEMBL25438937 | 0.84 | CES2 (0.41) | CES2CES1TSHRALDH1A1HSD17B10 | |
| SCHEMBL29137482 | 0.83 | SPHK2 (0.39) | CES2CES1TSHRALDH1A1LMNA | |
| SCHEMBL4074100 | 0.83 | LMNA (0.41) | TSHRALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL11130016 | 0.83 | EP300 (0.45) | LMNAHSD17B10MEN1KMT2APPARG | |
| SCHEMBL11130007 | 0.83 | EP300 (0.45) | LMNAHSD17B10MEN1KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251657-A1 | TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL | Sun Pharmaceutical Industries Limited (IN) | 2017-12-06 | — | — | EP | claimed |
| US-20170340649-A1 | TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-30 | — | — | US | claimed |
| CN-114949237-A | Vesicle | 斯昆申技术控股有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20210393655-A1 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-12-23 | — | — | US | disclosed |
| EP-3568379-B1 | A BROADBAND ANTI-REFLECTIVE SOL-GEL COATING COMPOSITION | FUNDACION TECNALIA RES & INNOVATION (ES) | 2021-03-10 | — | — | EP | disclosed |
| US-20210023007-A1 | BLENDED FORMULATIONS | SEQUESSOME TECH HOLDINGS LIMITED (US) | 2021-01-28 | — | — | US | disclosed |
| US-20190352223-A1 | BROADBAND ANTI-REFLECTIVE SOL-GEL COATING COMPOSITION | FUNDACION TECNALIA RESEARCH & INNOVATION (ES) | 2019-11-21 | — | — | US | disclosed |
| EP-3568379-A1 | A BROADBAND ANTI-REFLECTIVE SOL-GEL COATING COMPOSITION | Fundacíon Tecnalia Research & Innovation (ES) | 2019-11-20 | — | — | EP | disclosed |
| US-20190167588-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2019-06-06 | — | — | US | disclosed |
| WO-2018130701-A1 | A BROADBAND ANTI-REFLECTIVE SOL-GEL COATING COMPOSITION | FUNDACION TECNALIA RESEARCH & INNOVATION (ES) | 2018-07-19 | — | — | WO | disclosed |
| EP-3251657-A1 | TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL | Sun Pharmaceutical Industries Limited (IN) | 2017-12-06 | — | — | EP | disclosed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CEVC GREGOR | 2007-02-08 | — | — | US | disclosed |
| US-20060193789-A1 | Surfacant, film forming agent, water, gas propellant; plant and animal extracts and oils; may include malathion | FOAMIX LTD. (IL) | 2006-08-31 | — | — | US | disclosed |
| US-20050244342-A1 | Moisturizing foam containing lanolin | FOAMIX LTD. | 2005-11-03 | — | — | US | disclosed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | CES2 935/4885CES1 2798/4885TSHR 3410/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | CES2 935/4885CES1 2798/4885TSHR 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.